Table 3.
Univariable and multivariate analyses of predictive factors for PFS.
| Variable | Univariable | Multivariate | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Female | 0.41 (0.11-1.59) | 0.198 | ||
| Ann Arbor stage III-IV | 3.71 (0.64-21.56) | 0.144 | ||
| B symptom | 3.64 (0.92-14.43) | 0.066 | ||
| LDH > ULN | 11.39 (2.29-56.75) | 0.003* | 0.299 | |
| ECOG ≥ 2 | 1.43 (0.24-8.52) | 0.697 | ||
| Extranodal sites ≥1 | 0.64 (1.13-19.83) | 0.500 | ||
| IPI 3-5 | 4.06 (1.08-15.24) | 0.038* | ||
| Marrow involvement | 0.97 (0.26-3.67) | 0.964 | ||
| Prior lines of chemotherapy>2 | 4.36 (1.07-17.75) | 0.040* | 0.197 | |
| Prior ASCT | 0.82 (0.17-3.93) | 0.800 | ||
| Grade of CRS 3-4 | 3.53 (0.57-21.62) | 0.173 | ||
| Response Non-CR | 6.67 (1.63-27.37) | 0.009* | 0.227 | |
| DE | 5.36 (1.19-24.19) | 0.029* | 7.02 (1.16-42.45) | 0.047* |
| MYC + | 6.50 (1.52-27.72) | 0.012* | 0.054 | |
| BCL2 + | 1.79 (0.45-7.08) | 0.404 | ||
| MTV> 35.500 cm3 | 12.30 (2.99-50.57) | 0.001* | 0.106 | |
| TLG>55.000 | 6.13 (1.72-22.20) | 0.005* | 0.110 | |
| GLZLM_ZPCT ≤ 0.337 | 0.18 (0.05-0.67) | 0.010* | 0.056 | |
| SHAPE_VolumePET> 70.000 | 3.87 (0.74-20.31) | 0.110 | ||
| GLRLM_GLNUPET≤ 40.495 | 0.25 (0.05-1.40) | 0.115 | ||
| NGLDM_ContrastPET> 0.468 | 6.92 (1.08-15.24) | 0.002* | 15.16 (1.77-129.48) | 0.023* |
| SHAPE_SphericityPET> 0.467 | 4.74 (1.13-19.83) | 0.033* | 0.068 | |
*p < 0.05.